Objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.

Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion : ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218 / G. Timon, D. Ciardo, A. Bazani, G. Marvaso, G. Riva, S. Volpe, D.P. Rojas, G. Renne, G. Petralia, D. Zerini, C. Fodor, S. Dicuonzo, D. Maestri, F. Pansini, R. Cambria, F. Cattani, F. Golino, V. Scroffi, D. De Lorenzo, O. De Cobelli, R. Orecchia, B.A. Jereczek-Fossa. - In: BRITISH JOURNAL OF RADIOLOGY. - ISSN 0007-1285. - 91:1089(2018), pp. 20160725.1-20160725.6.

Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion : ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218

BAZANI, ALESSIA;Marvaso, Giulia;Riva, Giulia;Volpe, Stefania;Rojas, Damaris P;Petralia, Giuseppe;Dicuonzo, Samantha;De Cobelli, Ottavio;Orecchia, Roberto;Jereczek-Fossa, Barbara Alicja
2018

Abstract

Objective: To report preliminary results of a cutting edge extreme hypofractionated treatment with concomitant boost to the dominant lesion for patients with early stage prostate cancer (PCa). methods: AIRC-IG-13218 is a prospective Phase II trial started in June 2015. Patients with low and intermediate risk PCa who met the inclusion criteria underwent extreme hypofractionated radiotherapy to the prostate (36.25 Gy in 5 fractions) and a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) to 37.5 Gy. The DIL was identified by a multiparamentric MRI (mpMRI) co-registered with planning CT. Toxicity was assessed according to CTCAE v4.0 and RTOG/EORTC criteria. The preliminary evaluation of the first 13 patients was required to confirm the feasibility of the treatment before completing the enrollment of 65 patients. results: The first 13 patients completed the treatment between June 2015 and February 2016. With a median clinical follow-up of 17 months (range 11-26), no Grade 3 or 4 early toxicity was reported. Conclusions: Our preliminary data about early toxicity of an extreme hypofractionated schedule with concomitant boost on the DIL are encouraging. The higher number of patients expected for the trial and a longer follow-up are needed to confirm these results.
Aged; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prospective Studies; Prostate; Prostatic Neoplasms; Radiotherapy Dosage; Dose Hypofractionation; Radiotherapy, Computer-Assisted; Radiology, Nuclear Medicine and Imaging
Settore MED/24 - Urologia
BRITISH JOURNAL OF RADIOLOGY
Article (author)
File in questo prodotto:
File Dimensione Formato  
bjr.pdf

non disponibili

438.06 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/603202
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact